抗體藥物的全球增長機會

成本效益和高效的連續製造工藝和一次性生物反應器的使用，以及從開發到商業化的時間縮短，將推動全球抗體藥物市場的發展。被認為免疫腫瘤領域已成為抗體藥物市場的主要關注領域，尤其是隨著高靶向抗體藥物偶聯物和雙特異性抗體的出現。主要製造商正在尋求利用 CDMO 能力，相信市場格局在未來五年內可能會發生變化。

在完整的報告中，我們將調查全球抗體藥物市場、市場背景、分析市場上的各種影響因素、管道、技術趨勢、報銷方案、收入趨勢和預測、競爭環境、收入份額、分析增長機會等

內容

戰略要務

• 為什麼增長越來越難
• 戰略要務 8(TM)
• 三大戰略要務的市場影響
• 推動增長管道引擎 (TM) 的增長機會

增長機會分析

• 分析範圍
• 分類/定義
• 技術細節的定義
• 增長驅動力
• 抑制增長的因素
• 要點

成長環境

• 抗體療法：管線概覽
• 晚期抗體藥物的管線方案
• 潛在的治療領域
• 價值鏈：主要利益相關者
• 主要抗體藥物生產商
• 按地區劃分的主要工業趨勢
• 按管理途徑劃分的主要行業趨勢
• 主要行業趨勢：抗體藥物偶聯物
• 主要行業趨勢：技術進步
• 抗體藥價格分析
• 影響抗體藥價格的因素
• 抗體藥物的報銷方案
• 抗體藥物報銷：區域概覽
• 著名的抗體藥物聯盟與合作

收入預測

• 增長指標
• 調查方法
• 預測假設
• 收入預測
• 收入預測分析
• 收入預測：按技術分類
• 收入預測：按技術分類 - 討論
• 競爭環境
• 收入份額分析
• 值得關注的主要 ADC 開發人員

增長機會領域

• 增長機會 1：開發針對癌症免疫的多特異性抗體
• 增長機會 2：與 CDMO 和平台提供商合作，進一步發展 ADC
• ADC 的主要聯盟
• 增長機會 3：擴大單克隆抗體生物仿製藥的可及性和適應症

The Evolution of Next-generation Immuno-oncology Therapies for Multiple Tumor Antigens is Poised to Drive Market Growth

Market growth is likely to be fueled by the growing utilization of cost-effective and efficient continuous manufacturing processes and single-use bioreactors for production, which will also reduce the time between development and commercialization. Favorable regulatory reforms in emerging Asian countries are encouraging the manufacture and introduction of monoclonal antibody-based biosimilars, aiming to reduce the cost-burden of originator antibody therapies. The tailored approach used by manufacturers to improve the targeting efficiency of drug molecules toward multiple antigens is strengthening the pipeline portfolio of SMEs in the antibodies space and accelerating the pace of antibody drug development for cancer treatment.

Immuno-oncology remains a key focus area in the antibody therapeutics market, especially due to the emergence of highly target-specific antibody-drug conjugates and bispecific antibodies. Key manufacturers are striving to reduce in-house operations to leverage the capabilities of contract development and manufacturing organizations (CDMOs) with the aim of boosting innovation in the industry, which is likely to change the face of the market over the next 5 years.

Research Scope:

This Frost & Sullivan research service offers an outlook of the global antibody therapeutics market for 2022 and beyond, highlighting emerging trends and growth opportunities. As innovation takes center stage, the market is likely to witness remarkable growth in the near future, attributable to the focus on bi- and multi-specific antibodies, which has augmented investments by emerging start-ups in this space. Moreover, adoption of the antibody drug co-development strategy by key market participants is rising; they use it to leverage technologically advanced drug discovery and development platforms, especially for non-standard antibody therapies, including antibody-drug conjugates.

Research Highlights:

• Conventional and recombinant antibody therapeutics market size, including key segments, from 2022 to 2027

• Dynamics around product innovation and the reimbursement scenario

• Regulatory reforms and technological advancements driving value chain transformation

• Current and future R&D efforts and investment outlook

• Growth opportunities that market participants can focus on in the near future

Table of Contents

Strategic Imperatives

• Why is it Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Antibody Therapeutics Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

• Scope of Analysis
• Segmentation and Definition
• Definitions by Technology Subtype
• Growth Drivers
• Growth Restraints
• Key Takeaways

Growth Environment

• Antibody Therapeutics-Pipeline Snapshot
• Pipeline Scenario of Late-stage Antibody Therapeutics
• Potential Therapy Areas
• Value Chain-Key Stakeholders
• Key Antibody Therapeutics Manufacturers
• Key Industry Trends by Region
• Key Industry Trends by Region (continued)
• Key Industry Trends by Route of Administration
• Key Industry Trends-Antibody-Drug Conjugates
• Key Industry Trends-Technological Advancements
• Pricing Analysis of Antibody Therapeutics
• Factors Influencing the Pricing of Antibody Therapeutics
• Reimbursement Scenario for Antibody Therapeutics
• Reimbursement for Antibody Therapeutics-Regional Overview
• Notable Partnerships and Collaborations for Antibody Therapeutics
• Notable Partnerships and Collaborations for Antibody Therapeutics (continued)

Revenue Forecast

• Growth Metrics
• Research Methodology
• Forecast Assumptions
• Revenue Forecast
• Revenue Forecast Analysis
• Revenue Forecast by Technology
• Revenue Forecast by Technology Discussion
• Competitive Environment
• Revenue Share Analysis
• Key ADC Developers to Watch in 2022

Growth Opportunity Universe

• Growth Opportunity 1-Developing Multi-specific Antibodies for Immuno-oncology
• Growth Opportunity 1-Developing Multi-specific Antibodies for Immuno-oncology (continued)
• Growth Opportunity 2-Collaborating with CDMOs and Platform Providers for the Further Development of ADCs
• Growth Opportunity 2-Collaborating with CDMOs and Platform Providers for the Further Development of ADCs (continued)
• Key Alliances in ADCs
• Growth Opportunity 3-Expanding Accessibility to and Indications of Monoclonal Antibody Biosimilars
• Growth Opportunity 3-Expanding Accessibility to and Indications of Monoclonal Antibody Biosimilars (continued)
• List of Exhibits
• Legal Disclaimer